Myalgia may not be associated with severity of coronavirus disease 2019 (COVID-19).

20 Dear editor, A recent study based on the use of experimental artificial intelligence (AI) tool showed 70%–80% accuracy in predicting development of severe disease in coronavirus disease 2019 (COVID-19) based on predictive parameters alanine aminotransferase (ALT), myalgia and hemoglobin, whilst only 5 of 53 patients developed acute respiratory distress syndrome (ARDS), 2 of whom reporting myalgia. [1] It is commonly advocated that myalgia may reflect generalized inflammation and cytokine response. Multiple studies showed that myalgia is a common symptom at onset of COVID-19, seen in up to 36% of such patients. Therefore, in this short article we aim to further assess whether myalgia may be a reliable predictor of severe COVID-19 disease. A search in Medline (PubMed interface), Scopus, and Web of Science, utilizing the keywords “myalgia” AND “COVID-19” OR “Coronavirus 2019” OR “SARS-CoV-2” in all fields with no date or language restrictions was conducted. Search results were screened by title, abstract, and full text for those reporting data on prevalence of myalgia in patients developing severe or non-severe COVID-19 disease. Articles fitting the criteria with validated definition of “severe disease” (i.e., patient development of severe respiratory distress, requiring ICU admission, ventilatory support, or death) were incorporated into a pooled analysis. Computation of odds ratio (OR) and 95% confidence interval (CI) of myalgia in severe and non-severe COVID-19 disease was performed with MetaXL, software version 5.3 (EpiGear International Pty Ltd,. Sunrise Beach, Australia). Due to the limited number of studies, no risk of bias or publication bias assessment performed. This digital search enabled the identification of 16 articles after removing duplicates, 13 of which were excluded after review of title, abstract, and full text due to being review articles (n=3), did not pertain to COVID-19 disease (n=1), did not report prevalence of myalgia (n=8), or did not specify difference in myalgia from fatigue (n=1). Six additional studies were selected using reference search. Final pooled analysis included 9 studies with a total sample of 2,445 COVID-19 patients, 786 (32.1%) with severe disease. A total of 448 (18.3%) patients in the pooled sample presented with myalgias, 125 (19.3%) with severe COVID-19 disease and 296 (17.8%) without. Accordingly, myalgia was not found to be statistically associated with severe COVID-19 disease in any the nine individual studies, nor in our pooled analysis (OR 1.02; 95% CI 0.80–1.30; I=12%, Cochran’s Q, P=0.33) (Figure 1). The results of this pooled analysis of the current scientific literature suggest that the presence of myalgias shall not be considered a prognostic factor for severe COVID-19 disease. It is hence unlikely that adding the efficiency of stratification models for COVID-19 may be substantially improved by adding the presence of myalgia.